Cases & Deals

  • Home
  • Practices
  • Apsara establishes global patent portfolio for aquaporin-4 antibodies

Share

Apsara establishes global patent portfolio for aquaporin-4 antibodies

January 2015

Client(s) Apsara Therapeutics, Inc.

Jones Day represents Apsara Therapeutics, Inc. in the establishment of a global patent portfolio relating to aquaporin-4 (AQP4) antibodies for the treatment of neuromyelitis optica.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.